Navigation Links
Cardiovascular Meds May Be Beneficial in Alzheimer's Disease, According to MedPredict Report
Date:5/29/2008

SCOTTSDALE, Ariz., May 29 /PRNewswire/ -- MedPredict has published a new report designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area. The report, entitled "Thought Leader Insight & Analysis: Alzheimer's Disease," is based on in-depth interviews conducted with a panel of physician thought leaders actively involved in ongoing research.

"There is some real progress being made in development of diagnostics and treatments for Alzheimer's disease," said Dr. Jeffrey Berk, the primary author of this report. "We expect demand for diagnostics is going to skyrocket in concert with approvals of agents that alter the course of the disease. There are three objectives for an Alzheimer's diagnostic: to diagnose the disease, to track changes in the course of the disease, and to confirm the effect of drugs. Our panelists are most excited about amyloid imaging using a tracer chemical called PIB."

MedPredict's report discusses the emerging data associating cardiovascular drugs with slowing of disease progression and symptomatic benefit in Alzheimer's disease. According to Dr. Berk, "There is intriguing new data suggesting some antihypertensives might have a role in significantly reducing Alzheimer's dementia." Other disease modification approaches discussed by the panel include passive and active immunotherapies, gamma-secretase inhibitors and modulators, beta-secretase inhibitors, insulin related mechanisms, and others.

MedPredict's panel addresses other therapies in development for symptomatic benefit in Alzheimer's, aimed at improving cognition and physical symptoms, including cholinesterase inhibitors, NMDA antagonists, dimebolin, alpha-7 nicotinic acetylcholine agonists, and others.

Companies mentioned in this report: GE Healthcare, Avid, Bayer Schering, Siemens, C2N Diagnostics, Satoris, Novartis, Forest, Merz, Lundbeck, Daiichi Sankyo, Medivation, Abbott, AstraZeneca, Targacept, Roche, Memory, EnVivo, Wyeth, Epix, GlaxoSmithKline, Merck, Takeda, Sanofi-Aventis, Bristol Myers Squibb, Boehringer Ingelheim, Baxter, Lilly, Intellect Neurosciences, Elan, Myriad, AC Immune, Genentech, Affiris, TransTec, Pfizer, TorreyPines, Transition Therapeutics, Neurochem.

The full report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Study shows pine bark naturally reduces cardiovascular risk factors in diabetics
2. Study Shows Pine Bark Naturally Reduces Cardiovascular Risk Factors in Diabetics
3. American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD
4. Excess Drinking Boosts Cardiovascular Disease Risk
5. Cardica, Intuitive Surgical, MAQUET Cardiovascular and Transonic to Host Innovations in Revascularization Symposium
6. Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKlines Avandia Increases Nine-Fold Following Publication of Meta-Analysis
7. Spirit of the Heart: Preventing Cardiovascular Disease: A Community Call to Action
8. MAQUET Cardiovascular Launches HEARTSTRING III Proximal Seal System for Coronary Artery Bypass Graft Surgery
9. Terumo Cardiovascular Systems Responds to Allegations of Patent Infringement
10. Sexual dissatisfaction in postmenopausal women not linked to cardiovascular disease
11. Mary Cheney Joins the Cheney Cardiovascular Institute Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 ... ... Company, Cal Dining at the University of California Berkeley, and other leading institutions ... leverages the buying power of institutions to change the way animals are raised ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
Breaking Medicine Technology: